Molecular Oncology
Volume 3, Issue 5 , Pages 409-424 , December 2009

Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer

Received 16 July 2009 ,Revised 3 September 2009 ,Accepted 4 September 2009.

References 

  1. Acres B, Quoix E, Ramlau R, Lacoste G, Marie Bastien B, Tavernano A, et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J. Clin. Oncol. 2009;27:3027;(Abstract)
  2. Altorki N, Guarino M, Lee P, Pass HI, Filip E, Bauer T, et al. Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): a proof-of-concept phase II study. J. Clin. Oncol. 2008;26:7557;(Abstract)
  3. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, et al Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. 2004;172:3289–3296
  4. Bauman JE, Eaton KD, Martins RG. Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. Clin. Cancer Res. 2007;13:s4632–s4636
  5. Bauwens O, Ninane V. New diagnostic techniques in bronchial endoscopy. Rev. Mal. Respir. 2007;24:6S28–6S34
  6. Bepler G, Begum M, Simon GR. Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control. 2008;15:130–139
  7. Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, et al Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J. Clin. Oncol. 2008;26:1879–1885
  8. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, et al Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 2007;25:2727–2734
  9. Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, et al A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol. Biomarkers Prev. 2008;17:204–211
  10. Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert. Opin. Biol. Ther. 2008;8:951–968
  11. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas G, et al. Biomarker analyses from the phase III, placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J. Clin. Oncol. 2009;27:8020;(Abstract)
  12. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 2005;23:6674–6681
  13. Cappuzzo F, Ciuleanu T, Stelmakh L, Ciccenas S, Szszesna A, Juhasz E, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non progression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J. Clin. Oncol. 2009;27:8001;(Abstract)
  14. Charpidou A, Blatza D, Anagnostou V, Syrigos KN. Review. EGFR mutations in non-small cell lung cancer. Clinical implications. In Vivo. 2008;22:529–536
  15. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 2005;11:2063–2073
  16. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, et al. The role of the EGFR signaling in tumor microenvironment. J. Cell Physiol. 2008;214:559–567
  17. Fukuoka M, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients with advanced NSCLC. J. Clin. Oncol. 2009;27:8006;(Abstract)
  18. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert. Rev. Vaccines. 2007;6:723–739
  19. Gettinger S. Targeted therapy in advanced non-small-cell lung cancer. Semin. Respir. Crit. Care Med. 2008;29:291–301
  20. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007;56:641–648
  21. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat. Biotechnol. 2009;27:129–139
  22. Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics. 2009;10:59–68
  23. Hida T, Ogawa S, Park JC, Park JY, Shimizu J, Horio Y, et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert. Rev. Anticancer Ther. 2009;9:17–35
  24. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003;21:3798–3807
  25. Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc. Am. Thorac. Soc. 2009;6:206–217
  26. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199–208
  27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008;58:71–96
  28. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert. Opin. Biol. Ther. 2007;7:449–460
  29. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2009;27:2516–2522
  30. Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J. Hematol. Oncol. 2009;2:2
  31. Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009;115:1713–1722
  32. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005;353:172–187
  33. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002;20:709–760
  34. Krieg AM. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 2007;117:1184–1194
  35. Kruit WH, Suciu S, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, et al. Immunization with recombinant MAGE-A3 protein combined with Adjuvant Systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC melanoma group. J. Clin. Oncol. 2008;26:9065;(Abstract)
  36. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962–972
  37. Louahed J, Gruselle O, Gaulis T, Coche T, Eggermont AM, Kruit W, et al. Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients. J. Clin. Oncol. 2008;26:9045;(Abstract)
  38. Lucas S, Coulie PG. About human tumor antigens to be used in immunotherapy. Semin. Immunol. 2008;20:301–307
  39. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di CL, Sidoni A, et al High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann. Oncol. 2009;20:842–849
  40. Manegold C. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert. Rev. Anticancer Ther. 2008;8:689–699
  41. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, et al Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer. 2003;39:70–77
  42. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 2000;6:4055–4063
  43. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 2006;24:4721–4730
  44. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol. 2008;26:1452–1458
  45. Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, et al Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother. 2009;32:92–99
  46. O'Callaghan D, Rexhepaj E, Gately K, Gallagher WM, Delaney D, Kay E, et al. Effect of pattern of lymphocyte infiltration in NSCLC on outcome. J. Clin. Oncol. 2009;27:11079;(Abstract)
  47. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69:2514–2522
  48. Paccagnella A, Oniga F, Bearz A, Favaretto A, Clerici M, Barbieri F, et al Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II–III study. J. Clin. Oncol. 2006;24:681–687
  49. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 2005;560:11–18
  50. Pennell NA, Lynch TJ. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist. 2009;14:399–411
  51. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J. Clin. Oncol. 2008;26:3552–3559
  52. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525–1531
  53. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TMN classification for lung cancer. J. Thorac. Oncol. 2007;2:593–602
  54. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, et al A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J. Thorac. Oncol. 2008;3:735–744
  55. Reck M, Macha HN, Del Barco S, Cornes P, Vaissiere N, Morand M, et al. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer. 2009;64:319–325
  56. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, et al Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 2008;19:362–369
  57. Salam IA, Gaballa HE, Wahab NA. Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med. Oncol. 2009;26:161–166
  58. Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, Gillanders WE, et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 2007;30:40–53
  59. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, et al Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J. Thorac. Oncol. 2009;4:689–696
  60. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 2007;25:587–595
  61. Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest. 2005;128:3975–3984
  62. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005;115:739–746
  63. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc. Am. Thorac. Soc. 2009;6:233–241
  64. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, et al Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl. Cancer Inst. 2007;99:838–846
  65. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, de Smet C, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 1994;24:3038–3043
  66. Vansteenkiste J, Zielinski M, Linder A, Dahabreh IJ, Esteban E, Malinowski W, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2007;25:7554;(Abstract)
  67. Vansteenkiste J, Zielinski M, Linder A, Dahabreh IJ, Esteban E, Malinowski W, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2008;26:9045;(Abstract)
  68. Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, et al Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J. Immunother. 2004;27:124–135
  69. Yamashita S, Chujo M, Miyawaki M, Tokuishi K, Anami K, Yamamoto S, et al. Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 2009;28:22
  70. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. 2001;19:432–441
  71. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008;8:59–73

PII: S1574-7891(09)00110-0

doi: 10.1016/j.molonc.2009.09.001

Molecular Oncology
Volume 3, Issue 5 , Pages 409-424 , December 2009

Article Tools

* Image Usage & Resolution